A study of CC-chemokine receptor 5 (CCR5) polymorphism on the outcome of HCV therapy in Egyptian patients
| dc.Affiliation | October University for modern sciences and Arts (MSA) | |
| dc.contributor.author | Omran M.H. | |
| dc.contributor.author | Khamis M. | |
| dc.contributor.author | Nasr N. | |
| dc.contributor.author | Massoud A.A. | |
| dc.contributor.author | Youssef S.S. | |
| dc.contributor.author | Bader El Din N.G. | |
| dc.contributor.author | Dawood R.M. | |
| dc.contributor.author | Atef K. | |
| dc.contributor.author | Moustafa R.I. | |
| dc.contributor.author | Nabil W. | |
| dc.contributor.author | Tabll A.A. | |
| dc.contributor.author | El Awady M.K. | |
| dc.contributor.other | Microbial Biotechnology Department | |
| dc.contributor.other | Genetic Engineering Division | |
| dc.contributor.other | National Research Centre | |
| dc.contributor.other | Cairo | |
| dc.contributor.other | Egypt; Zoology Department | |
| dc.contributor.other | Modern Science and Arts University (MSA) | |
| dc.contributor.other | Cairo | |
| dc.contributor.other | Egypt; Zoology Department | |
| dc.contributor.other | Tanta University | |
| dc.contributor.other | Cairo | |
| dc.contributor.other | Egypt | |
| dc.date.accessioned | 2020-01-09T20:42:20Z | |
| dc.date.available | 2020-01-09T20:42:20Z | |
| dc.date.issued | 2013 | |
| dc.description | Scopus | |
| dc.description.abstract | Background: Chronic hepatitis C virus (HCV) infection is a globally serious public health issue. Objectives: In this study, we investigated CC chemokine receptor 5 (CCR5-59029) polymorphism which is considered an important component of the immune system in determining the outcome of HCV infection. Its critical role as a marker in response to interferon therapy of HCV infection is also investigated besides its effect on other clinical patient factors. Patients and Methods: This study was conducted on 82 Egyptian patients with chronic Hepatitis C Virus (HCV) infection who received PEG-INF + Ribavirin treatment for 48 weeks. The study was also conducted on 50 healthy controls (with negative results for HCV antibody and RNA PCR). Full history of patients in this study was recorded. Clinical and histological examinations, qualitative HCV nested RT-PCR, quantitative real -time PCR, and genotyping of HCV RNA genome were performed. CCR5-59029 polymorphism with nucleotide substitution from G to A was amplified. The amplicons were digested with restriction endonuclease Bsp 1286I, and produced RFLPs of the CCR5 genotypes were determined. Results: The present study showed a significant association between the functional SNP of CCR5 gene and the viral response to interferon in chronic HCV Egyptian patients. It was shown that the higher fibrosis stages (F2-F4) had significant association with nonresponse to treatment compared to the lower fibrosis stages (F0-F1) (95% confidence: 5.497 - 55.074, P = 0.0001). In addition, worse liver activity grade (A2-A3) had a very highly significant association with non-responder HCV patients compared to those with better liver activity grade (A1) (95% confidence: 2.242 - 20.974, P = 0.0007). Most importantly HCV patients with G allele had a high significant association with nonresponse to treatment, higher fibrosis stages and worse liver activity grades, while the A allele had a high significant association with sustained response, low fibrosis stages and relatively better liver activity grade (95% confidence: 3.347 - 15.036, P = 0.0001). Conclusions: SNPs within the CCR5 gene should be considered as an important factor used in combination with other host gene SNPs when developing a mathematical model for anticipating response to HCV therapy. � 2013, Kowsar Corp. | en_US |
| dc.identifier.doi | https://doi.org/10.5812/hepatmon.13721 | |
| dc.identifier.doi | PubMedID | |
| dc.identifier.issn | 1735143X | |
| dc.identifier.other | https://doi.org/10.5812/hepatmon.13721 | |
| dc.identifier.other | PubMedID | |
| dc.identifier.uri | https://t.ly/8pp1z | |
| dc.language.iso | English | en_US |
| dc.relation.ispartofseries | Hepatitis Monthly | |
| dc.relation.ispartofseries | 13 | |
| dc.subject | Chemokines | en_US |
| dc.subject | Hepatitis C | en_US |
| dc.subject | Host-derived cellular factor | en_US |
| dc.subject | Interferons | en_US |
| dc.subject | alpha fetoprotein | en_US |
| dc.subject | chemokine receptor CCR5 | en_US |
| dc.subject | peginterferon | en_US |
| dc.subject | ribavirin | en_US |
| dc.subject | virus RNA | en_US |
| dc.subject | adult | en_US |
| dc.subject | article | en_US |
| dc.subject | body weight | en_US |
| dc.subject | controlled study | en_US |
| dc.subject | DNA extraction | en_US |
| dc.subject | DNA polymorphism | en_US |
| dc.subject | female | en_US |
| dc.subject | gene frequency | en_US |
| dc.subject | genetic association | en_US |
| dc.subject | genotyping technique | en_US |
| dc.subject | hepatitis C | en_US |
| dc.subject | human | en_US |
| dc.subject | liver fibrosis | en_US |
| dc.subject | liver function | en_US |
| dc.subject | major clinical study | en_US |
| dc.subject | male | en_US |
| dc.subject | real time polymerase chain reaction | en_US |
| dc.subject | restriction fragment length polymorphism | en_US |
| dc.subject | reverse transcription polymerase chain reaction | en_US |
| dc.subject | single nucleotide polymorphism | en_US |
| dc.subject | treatment outcome | en_US |
| dc.subject | virus genome | en_US |
| dc.subject | virus load | en_US |
| dc.title | A study of CC-chemokine receptor 5 (CCR5) polymorphism on the outcome of HCV therapy in Egyptian patients | en_US |
| dc.type | Article | en_US |
| dcterms.isReferencedBy | Strickland, G.T., Elhefni, H., Salman, T., Waked, I., Abdel-Hamid, M., Mikhail, N.N., Role of hepatitis C infection in chronic liver disease in Egypt (2002) Am J Trop Med Hyg, 67 (4), pp. 436-442; El-Zayadi, A.R., Attia, M., Barakat, E.M., Badran, H.M., Hamdy, H., El-Tawil, A., Response of hepatitis C genotype-4 naive patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: A non-randomized controlled study (2005) Am J Gastroenterol, 100 (11), pp. 2447-2452; Brok, J., Gluud, L.L., Gluud, C., Effects of adding ribavirin to interferon to treat chronic hepatitis C infection: A systematic review and meta-analysis of randomized trials (2005) Arch Intern Med, 165 (19), pp. 2206-2212; Ward, R.P., Kugelmas, M., Using pegylated interferon and ribavirin to treat patients with chronic hepatitis C (2005) Am Fam Physician, 72 (4), pp. 655-662; Rocha, D., Gut, I., Jeffreys, A.J., Kwok, P.Y., Brookes, A.J., Chanock, S.J., Seventh international meeting on single nucleotide polymorphism and complex genome analysis: 'ever bigger scans and an increasingly variable genome' (2006) Hum Genet, 119 (4), pp. 451-456; Houldsworth, A., Metzner, M., Rossol, S., Shaw, S., Kaminski, E., Demaine, A.G., Polymorphisms in the IL-12B gene and outcome of HCV infection (2005) J Interferon Cytokine Res, 25 (5), pp. 271-276; Konishi, I., Horiike, N., Hiasa, Y., Michitaka, K., Onji, M., CCR5 promoter polymorphism influences the interferon response of patients with chronic hepatitis C in Japan (2004) Intervirology, 47 (2), pp. 114-120; Omran, M.H., Fotouh, B.E., Youssef, S.S., Ibrahim, N.E., Nabil, W., Mahdy el, S.M., Association between low molecular polypeptide 7 single nucleotide polymorphism and response to therapy in hepatitis C virus infection (2013) World J Hepatol, 5 (3), pp. 97-103; Charo, I.F., Ransohoff, R.M., The many roles of chemokines and chemokine receptors in inflammation (2006) N Engl J Med, 354 (6), pp. 610-621; Bertoletti, A., Maini, M.K., Protection or damage: A dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection? (2000) Curr Opin Immunol, 12 (4), pp. 403-408; Ohno, O., Mizokami, M., Wu, R.R., Saleh, M.G., Ohba, K., Orito, E., New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a (1997) J Clin Microbiol, 35 (1), pp. 201-207; Armitage, P.G., (2000) Statistical methods in medical research, , 3rd Edition ed: Science; Riffenburgh, R.H., (2006) Statistics in Medicine, , 2nd Edition edUSA: Elsevier Academic press; Lechner, F., Wong, D.K., Dunbar, P.R., Chapman, R., Chung, R.T., Dohrenwend, P., Analysis of successful immune responses in persons infected with hepatitis C virus (2000) J Exp Med, 191 (9), pp. 1499-1512; Larrubia, J.R., Benito-Martinez, S., Calvino, M., Sanz-de-Villalobos, E., Parra-Cid, T., Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection (2008) World J Gastroenterol, 14 (47), pp. 7149-7159; Shiffman, M.L., Suter, F., Bacon, B.R., Nelson, D., Harley, H., Sola, R., Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3 (2007) N Engl J Med, 357 (2), pp. 124-134; Reddy, K.R., Messinger, D., Popescu, M., Hadziyannis, S.J., Peginterferon alpha-2a (40 kDa) and ribavirin: Comparable rates of sustained virological response in sub-sets of older and younger HCV genotype 1 patients (2009) J Viral Hepat, 16 (10), pp. 724-731; Sugimoto, Y., Kuzushita, N., Takehara, T., Kanto, T., Tatsumi, T., Miyagi, T., A single nucleotide polymorphism of the low molecular mass polypeptide 7 gene influences the interferon response in patients with chronic hepatitis C (2002) J Viral Hepat, 9 (5), pp. 377-384; Yuan, Y., Shimizu, I., Shen, M., Aoyagi, E., Takenaka, H., Itagaki, T., Effects of estradiol and progesterone on the proinflammatory cytokine production by mononuclear cells from patients with chronic hepatitis C (2008) World J Gastroenterol, 14 (14), pp. 2200-2207; Berg, T., von Wagner, M., Nasser, S., Sarrazin, C., Heintges, T., Gerlach, T., Extended treatment duration for hepatitis C virus type 1: Comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin (2006) Gastroenterology, 130 (4), pp. 1086-1097; Asselah, T., Estrabaud, E., Bieche, I., Lapalus, M., De Muynck, S., Vidaud, M., Hepatitis C: Viral and host factors associated with non-response to pegylated interferon plus ribavirin (2010) Liver Int, 30 (9), pp. 1259-1269; Lindsay, K.L., Introduction to therapy of hepatitis C (2002) Hepatology, 36 (5 SUPPL. 1), pp. S114-S120; Blanca, O.C., Predictive factors for response to treatment of Chronic Hepatitis (2006) Ann hepatology, 5, pp. 24-28; Nadeem, A., Hussain, M.M., Aslam, M., Hussain, T., Butt, I.F., Ali Khan, S., Association of response to combined interferon alpha-2b and ribavirin therapy in patients of chronic hepatitis c with serum alanine aminotransferase levels and severity of the disease on liver biopsy (2009) J Ayub Med Coll Abbottabad, 21 (2), pp. 103-106; Ferenci, P., Predictors of response to therapy for chronic hepatitis C (2004) Semin Liver Dis, 24 (SUPPL. 2), pp. 25-31; Males, S., Gad, R.R., Esmat, G., Abobakr, H., Anwar, M., Rekacewicz, C., Serum alpha-foetoprotein level predicts treatment outcome in chronic hepatitis C (2007) Antivir Ther, 12 (5), pp. 797-803; Ksiaa Cheikh Rouhou, L., Gorgi, Y.L., Skhiri, H.A., Aouadi, H., Ayed, S.J., Sfar, I., Chemokine and chemokine receptor gene polymorphism in Tunisian hemodialysis patients with HCV infection (2011) Arab J Nephrol Transplant, 4 (3), pp. 117-124; Promrat, K., McDermott, D.H., Gonzalez, C.M., Kleiner, D.E., Koziol, D.E., Lessie, M., Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C (2003) Gastroenterology, 124 (2), pp. 352-360; Coenen, M., Nattermann, J., The role of CCR5 in HCV infection (2010) Eur J Med Res, 15 (3), pp. 97-101; Shieh, B., Liau, Y.E., Hsieh, P.S., Yan, Y.P., Wang, S.T., Li, C., Influence of nucleotide polymorphisms in the CCR2 gene and the CCR5 promoter on the expression of cell surface CCR5 and CXCR4 (2000) Int Immunol, 12 (9), pp. 1311-1318; Ajuebor, M.N., Carey, J.A., Swain, M.G., CCR5 in T cell-mediated liver diseases: What's going on? (2006) J Immunol, 177 (4), pp. 2039-2045 | |
| dcterms.source | Scopus |